50 Studies Every Psychiatrist Should Know

Description

50 Studies Every Psychiatrist Should Know presents key studies that have shaped the practice of psychiatry. Selected using a rigorous methodology, the studies cover topics including: psychotic disorders, depressive disorders, women's mental health, child and adolescent disorders, and epidemiological studies. For each study, a concise summary is presented with an emphasis on the results and limitations of the study, and its implications for practice. An illustrative clinical case concludes each review, followed by brief information on other relevant studies. This book is a must-read for health care professionals and anyone who wants to learn more about the data behind clinical practice. Contents Preface Acknowledgments About the Editors Contributors Section 1: Anxiety Disorders 1. Cognitive Behavioral Therapy, Imipramine, or Their Combination for Panic Disorder • Amanda Sun and Tobias Wasser 2. Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placebo in Generalized Social Phobia • Erin Habecker and Tobias Wasser Section 2: Bipolar Disorder 3. Lithium Plus Valproate Combination versus Monotherapy for Relapse Prevention in Bipolar I Disorder (BALANCE) • João Paulo De Aquino and Robert Beech 4. Mood Stabilizer Monotherapy versus Adjunctive Antidepressant for Bipolar Depression: The STEP-BD Trial • João Paulo De Aquino and Robert Beech 5. Suicide Risk in Bipolar Disorder: Comparing Lithium, Divalproex, and Carbamazepine • Rachel Katz and Robert Beech 6. The Long-Term Natural History of Bipolar I Disorder • Zachary Engler and Robert Beech Section 3: Child and Adolescent Disorders 7. The Multimodal Treatment Study of Children with Attention Deficit/Hyperactivity Disorder (MTA) • Michael H. Bloch 8. Adolescents with SSRI- Resistant Depression: The TORDIA Trial • Amalia Londono Tobon and Hanna E. Stevens 9. Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study • J. Corey Williams and Hanna E. Stevens 10. Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety: CAMS • David Saunders, Andres Martin, and Jerome H. Taylor 11. Predictors of Suicidal Events: The Treatment of Adolescent Suicide Attempters (TASA) Study • Michael Maksimowski and Zheala Qayyum 12. Cognitive Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents with OCD • Falisha Gilman and Zheala Qayyum 13. Initial Treatment of Bipolar I Disorder in Children and Adolescents: The TEAM Trial • Stephanie Ng and Andres Martin 14. The Treatment for Adolescents with Depression Study (TADS) • Zachary Engler and Zheala Qayyum Section 4: Cognitive Disorders: Delirium/Dementia 15. Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer’s Disease: CATIE-AD • Adam P. Mecca and Rajesh R. Tampi 16. Risk of Death with Atypical Antipsychotic Medications for Dementia • Adam P. Mecca and Rajesh R. Tampi 17. Treatment of Delirium in Hospitalized AIDS Patients: A Double-Blind Trial of Haloperidol, Chlorpromazine, and Lorazepam • Amanda Sun and Rajesh R. Tampi 18. Memantine in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil • Brandon M. Kitay and Rajesh R. Tampi Section 5: Epidemiology 19. Global Burden of Mental and Substance Use Disorders • Stephanie Yarnell and Ellen Edens 20. Prevalence and Severity of Psychiatric Comorbidities: The National Comorbidity Survey Replication (NCS-R) • Stephanie Yarnell and Ellen Edens Section 6: Insomnia 21. Behavioral and/or Pharmacotherapy for Older Patients with Insomnia • Robert Ross and Rajesh R. Tampi Section 7: Major Depressive Disorder 22. Treatment of Depression in Patients with Alcohol or Drug Dependence: A Meta-Analysis • J. Corey Williams and Gustavo A. Angarita Africano 23. Suicidality in Pediatric Patients Treated with Antidepressant Drugs: FDA Meta-Analysis • David Saunders and Michael H. Bloch 24. National Institute of Mental Health (NIMH) Treatment of Depression Collaborative Research Program • Joseph J. Taylor and Robert Ostroff 25. Efficacy and Safety of Electroconvulsive Therapy in Depressive Disorders: A Systematic Review and Meta- Analysis • Joseph J. Taylor and Robert Ostroff 26. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration • Michael Maksimowski and Zheala Qayyum 27. Sequenced Treatment Alternatives to Relieve Depression: STAR*D • Eric Lin and Pochu Ho 28. Cognitive Therapy versus Medication in the Treatment of Moderate to Severe Depression • Daniel Barron and Robert Ostroff Section 8: Obsessive-Compulsive Disorder 29. Exposure and Ritual Prevention, Clomipramine, or Their Combination for Obsessive-Compulsive Disorder • Brandon M. Kitay and Michael H. Bloch 30. Meta- Analysis of the Dose–Response Relationship of SSRIs in Adult Patients with Obsessive-Compulsive Disorder • Eunice Yuen and Michael H. Bloch Section 9: Personality Disorders 31. Psychotherapy for Borderline Personality Disorder: A Multiwave Study • David Grunwald, Erica Robinson, and Sarah Fineberg 32. Dialectical Behavior Therapy versus Community Treatment by Experts for Reducing Suicidal Behaviors among Patients with Borderline Personality Disorder • David Saunders, Erica Robinson, and Sarah Fineberg 33. Ten-Year Course of Borderline Personality Disorder: The Collaborative Longitudinal Personality Disorders Study • Kevin Johnson, Erica Robinson, and Sarah Fineberg Section 10: Psychiatry in Primary Care 34. Depressive Symptoms and Health-Related Quality of Life: The Heart and Soul Study • Amalia Londono Tobon and Catherine Chiles 35. The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial • Nikhil Gupta and Catherine Chiles Section 11: Women’s Mental Health 36. Buprenorphine versus Methadone During Pregnancy: The MOTHER Trial • Rachel Wurmser and Kirsten Wilkins Section 12: Schizophrenia 37. QTc-Interval Abnormalities and Psychotropic Drug Therapy in Psychiatric Patients • Amanda Sun and Vinod H. Srihari 38. Tardive Dyskinesia with Atypical versus Conventional Antipsychotic Medications • Emma Lo and Cenk Tek 39. Effectiveness of Antipsychotics in the Treatment of Schizophrenia: CATIE Phase 1 • Chadrick Lane and Mohini Ranganathan 40. Clozapine for Treatment- Resistant Schizophrenia • Chadrick Lane and Vinod H. Srihari 41. Effectiveness of Clozapine versus Other Atypical Antipsychotics: Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) • Eunice Yuen and Cenk Tek 42. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death • Hamilton Hicks and Cenk Tek 43. Switching Antipsychotics to Reduce Metabolic Risk: The CAMP Trial • Eric Lin and John Cahill 44. Cost Utility of Atypical Antipsychotics: CUtLASS-1 • Nikhil Gupta and John Cahill 45. North American Prodrome Longitudinal Study • Nikhil Gupta and Vinod H. Srihari 46. Clozapine for Suicidality in Schizophrenia: The International Suicide Prevention Trial (InterSePT) • Daniel Barron and Noah Capurso 47. A Cohort Study of Oral and Depot Antipsychotics after First Hospitalization for Schizophrenia • Stephanie Ng and Cenk Tek Section 13: Substance Use Disorders 48. Methadone Maintenance versus Detoxification and Psychosocial Treatment for Opioid Dependence: The M180 Study • Hamilton Hicks and Srinivas Muvvala 49. Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study • Kevin Johnson and Srinivas Muvvala 50. Levomethadyl Acetate versus Buprenorphine versus Methadone for Opioid Dependence • Robert Ross and Brian Fuehrlein Index